Ibrutinib

Evidence Level: L5 Predicted Indications: 52

Quick Overview

Item Value
Drug Name Ibrutinib
DrugBank ID DB09053
Brand Names (EU) Imbruvica
Evidence Level L5
Predicted Indications 52
Top Prediction Score 95.02%

Approved Indication (EMA)

Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without Imbruvica, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).Imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory MCL.Imbru

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 mantle cell lymphoma 95.02% DL
2 polyclonal hypergammaglobulinemia 91.75% DL
3 monoclonal paraproteinemia disease 91.16% DL
4 thyroid gland mucosa-associated lymphoid tissue lymphoma 88.43% DL
5 small intestinal mucosa-associated lymphoid tissue lymphoma 88.36% DL
6 small intestinal Burkitt lymphoma 88.32% DL
7 breast mucosa-associated lymphoid tissue lymphoma 88.07% DL
8 tonsillar lymphoma 88.05% DL
9 marginal zone lymphoma 87.96% DL
10 extracutaneous mastocytoma 87.74% DL
11 neoplasm of mature B-cells 86.55% DL
12 familial thrombocytosis 85.84% DL
13 lymphoma, non-Hodgkin, familial 85.59% DL
14 Richter syndrome 85.26% DL
15 macroglobulinemia 84.90% DL
16 B-cell neoplasm 84.53% DL
17 follicular lymphoma, susceptibility to, 1 83.55% DL
18 lymphoplasmacytic lymphoma 83.33% DL
19 metastatic neoplasm 83.10% DL
20 malignant spiradenoma 82.99% DL

Showing top 20 of 52 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.